# A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)

> **NCT05540873** · PHASE1 · UNKNOWN · sponsor: **CellabMED** · enrollment: 18 (estimated)

## Conditions studied

- Recurrent Malignant Glioma

## Interventions

- **DRUG:** YYB-103

## Key facts

- **NCT ID:** NCT05540873
- **Lead sponsor:** CellabMED
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-18
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-04-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540873, "A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05540873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*